Obsidio™ Conformable Embolic Registry
← catalyst calendarSponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
125actual
Sites
20
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-19 | actual | When the study began enrolling |
| Primary completion | 2025-09-09 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-09 | actual | The whole study's end, after follow-up |
| First posted | 2023-12-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Hypervascular Tumors
- Bleeding
- Hemorrhage
Intervention
- Device: Obsidio™ Conformable Embolic
Primary outcomes
what the primary-completion date above is the date OFPrimary effectiveness endpoint
measured Immediately following index procedure
Primary safety endpoint
measured 30 days following index procedure
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed